In last trading session, Monte Rosa Therapeutics Inc (NASDAQ:GLUE) saw 0.42 million shares changing hands with its beta currently measuring 1.37. Company’s recent per share price level of $3.98 trading at $0.11 or 2.84% at ring of the bell on the day assigns it a market valuation of $244.81M. That closing price of GLUE’s stock is at a discount of -211.56% from its 52-week high price of $12.40 and is indicating a premium of 19.35% from its 52-week low price of $3.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.37 million shares which gives us an average trading volume of 690.54K if we extend that period to 3-months.
For Monte Rosa Therapeutics Inc (GLUE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) trade information
Upright in the green during last session for gaining 2.84%, in the last five days GLUE remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $3.98 price level, adding 10.16% to its value on the day. Monte Rosa Therapeutics Inc’s shares saw a change of -42.65% in year-to-date performance and have moved -2.69% in past 5-day. Monte Rosa Therapeutics Inc (NASDAQ:GLUE) showed a performance of -9.75% in past 30-days. Number of shares sold short was 7.88 million shares which calculate 9.49 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -41.09% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 20.27% while estimates for its earnings growth in next 5 years are of -14.31%.
Monte Rosa Therapeutics Inc (NASDAQ:GLUE)’s Major holders
Insiders are in possession of 0.72% of company’s total shares while institution are holding 100.79 percent of that, with stock having share float percentage of 101.52%. Investors also watch the number of corporate investors in a company very closely, which is 100.79% institutions for Monte Rosa Therapeutics Inc that are currently holding shares of the company. NEA MANAGEMENT COMPANY, LLC is the top institutional holder at GLUE for having 7.69 million shares of worth $28.77 million. And as of 2024-06-30, it was holding 10.7986 of the company’s outstanding shares.
The second largest institutional holder is PRICE T ROWE ASSOCIATES INC /MD/, which was holding about 5.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.3915 of outstanding shares, having a total worth of $22.36 million.
On the other hand, T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.4 shares of worth $13.55 million or 5.53% of the total outstanding shares. The later fund manager was in possession of 1.92 shares on Dec 31, 2024 , making its stake of worth around $7.65 million in the company or a holder of 3.12% of company’s stock.
